Description
Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved reference biologic drug. In cancer supportive care, biosimilars have become increasingly important for managing various aspects of cancer treatment, including supportive therapies. One significant application of biosimilars in cancer supportive care is in the management of chemotherapy-induced neutropenia. Neutropenia, characterized by low levels of neutrophils (a type of white blood cell), is a common side effect of chemotherapy that can increase the risk of infections. Biosimilar versions of granulocyte colony-stimulating factors (G-CSFs), such as filgrastim and pegfilgrastim, are used to stimulate the production of neutrophils and reduce the duration and severity of neutropenia.
Résumé
- Biosimilars are gaining importance due to rising medication costs, which can burden patients, families, and healthcare systems. Maintaining patient access to medication is a priority, and biosimilars offer a potential solution by mitigating financial toxicity and reducing out-of-pocket expenses for patients.
- Biosimilars undergo rigorous approval processes by agencies like the FDA and EMA, similar to brand-name drugs, taking 8-10 years. The focus is on characterizing the molecule's similarity to the original, with less reliance on extensive phase trials due to the existing data from the brand-name drug. Post-market data collection further validates biosimilar performance in real-world scenarios.
- Biosimilars are not generics. They are complex molecules derived from living organisms and require efficacy and safety data, unlike generics, which are simpler and easier to reproduce. Extrapolation allows biosimilars approved for one indication to be used for others with a common mechanism of action, provided safety and efficacy are demonstrated.
- The first approved biosimilar, Zarzio (filgrastim), revolutionized drug affordability. Studies show biosimilars like Zarzio are comparable in efficacy and safety to their brand-name counterparts in preventing severe neutropenia. Increased confidence in biosimilars has led to wider adoption, reducing healthcare costs for patients, insurers, and governments.
- Biosimilars extend beyond oncology, including rheumatology and gastroenterology. Data from the UK's NHS shows biosimilar use increased fivefold, reaching more patients and still saving money. This has expanded biosimilar use beyond high-risk patients to include early and low-risk cases, aiming to reduce hospitalization and antibiotic usage.
- Biosimilars offer comparable quality, efficacy, and safety to reference products, providing greater patient access to affordable drugs. Cost savings enable better healthcare resource allocation, reducing financial burdens and treatment compromises. Both Zarzio and Zixensio have demonstrated comparable efficacy and safety to their brand-name counterparts, integrating biosimilars into international and national guidelines.
Exemple de certificat
À propos des intervenants
Dr Abdul Rahman Agha El Kinge
Anciens élèves - Centre médical de l'Université américaine de Beyrouth
Divulgation financière
Commentaires
Commentaires
Vous devez être connecté pour laisser un commentaire.